stem cell transplant for lymphoma

Stem cell transplant remains one of the most effective treatments for lymphoma that has relapsed or stopped responding to standard chemotherapy, curing roughly half of eligible patients with relapsed Hodgkin lymphoma and producing long-term remissions in many cases of aggressive non-Hodgkin lymphoma. The procedure comes in two fundamentally different forms, autologous (using your own stem cells) and allogeneic (using a donor’s), and the choice between them depends on the type of lymphoma, how it has responded to prior treatment, and your overall fitness. While newer therapies like CAR-T cells have changed the conversation, transplant still holds a central role in treatment for many patients.

Autologous Transplant and When It Is Used

The most common transplant approach for lymphoma is autologous, meaning your own blood-forming stem cells are collected before treatment, stored, and then returned to you after a round of very high-dose chemotherapy. The logic is straightforward: higher doses of chemotherapy kill more cancer cells, but they also destroy the bone marrow. Giving back your own stem cells rescues the marrow so it can rebuild. For relapsed or refractory Hodgkin lymphoma, this sequence of salvage chemotherapy followed by high-dose chemotherapy and autologous transplant is considered the global standard of care, curing about half of patients who make it to transplant.¹ The same general framework applies to aggressive forms of non-Hodgkin lymphoma, particularly diffuse large B-cell lymphoma (DLBCL), where transplant is offered to patients whose disease responds to second-line chemotherapy.

A large observational study comparing two common conditioning regimens, BEAM and FEAM, across more than a thousand lymphoma patients found two-year overall survival of about 84% and progression-free survival of roughly 70%, with no meaningful difference between the two regimens in terms of disease control.² The study did find higher infection-related death with the fotemustine-based FEAM regimen, which is worth discussing with your transplant team if this substitution comes up.

Older patients were once routinely excluded from transplant, but that has changed. An analysis of patients aged 60 and above who underwent autologous transplant for non-Hodgkin lymphoma reported three-year overall survival of 73% and early transplant-related mortality of about 4%, demonstrating that the procedure is feasible and effective in carefully selected older adults.³ Fitness matters more than a number on a birthday card.

Collecting Enough Stem Cells

Before an autologous transplant can happen, doctors need to harvest enough stem cells from your blood. This process, called mobilization, typically involves injections of a growth factor called G-CSF that pushes stem cells out of the bone marrow into the bloodstream, where they can be collected through a procedure similar to blood donation. The challenge is that not everyone mobilizes well, especially patients who have received extensive prior chemotherapy or radiation.

Adding a drug called plerixafor to G-CSF dramatically improves collection rates. A meta-analysis found that about 65% of patients given both drugs hit their target stem cell yield, compared with only about 34% given G-CSF alone.⁴ The benefit was especially pronounced in Hodgkin lymphoma patients, where the odds of reaching target were roughly twelve times higher with the combination. In a phase II trial focused on Hodgkin lymphoma, 95% of patients who received G-CSF plus plerixafor collected at least the minimum stem cell dose needed to proceed to transplant.⁵

A prospective trial using the combination as a first-line mobilization strategy reported that 96% of lymphoma and myeloma patients collected the minimum required dose, often within a single day of collection.⁶ Reaching the optimal (higher) target was harder for non-Hodgkin lymphoma patients specifically, with about 48% hitting that mark versus 89% of myeloma patients. If your team mentions concern about poor mobilization, plerixafor is typically the solution.

Allogeneic Transplant and the Graft-versus-Lymphoma Effect

Allogeneic transplant uses stem cells from a donor, either a matched sibling, an unrelated volunteer from a registry, or a half-matched (haploidentical) family member. It works differently from autologous transplant in a fundamental way: beyond the high-dose chemotherapy, the donor’s immune system itself attacks residual lymphoma cells. This is called the graft-versus-lymphoma effect, and it is the primary reason allogeneic transplant can succeed even when autologous transplant has failed.

Research in animal models showed that this anti-tumor activity is driven by a specific type of donor immune cell and requires functional killing pathways to exert its full effect.⁷ In human patients, the same principle holds: the donor immune system patrols for and destroys lymphoma cells that survive conditioning. The flip side is that the donor’s immune cells can also attack healthy tissues, causing graft-versus-host disease (GVHD), which is the major trade-off with this approach.

Allogeneic transplant is generally reserved for patients whose disease has returned after an autologous transplant, those with lymphoma subtypes that are unlikely to respond to autologous transplant alone, or increasingly, patients who have relapsed after CAR-T cell therapy.

Reduced-Intensity Conditioning and Donor Choices

Traditional allogeneic transplant used very intense chemotherapy and sometimes whole-body radiation to wipe out the bone marrow before infusing donor cells. This approach carried high rates of treatment-related death, especially in older or sicker patients. Over the past two decades, reduced-intensity conditioning has become the preferred platform for most lymphoma patients undergoing allogeneic transplant, offering a better balance between disease control and side effects by relying more on the graft-versus-lymphoma effect and less on brute-force chemotherapy.⁸ This shift has opened allogeneic transplant to patients who would not have been considered candidates before, including those who are older or who have organ damage from prior treatments.⁹

Finding a donor used to be a major barrier, but haploidentical transplant, which uses a half-matched family member, has changed the landscape. A large registry analysis comparing haploidentical donors with fully matched sibling donors in lymphoma patients who received reduced-intensity conditioning found no meaningful differences: three-year progression-free survival was 48% in both groups, overall survival was about 61% versus 62%, and transplant-related mortality was similar.¹⁰ This means nearly every patient has a potential donor, since most people have at least one haploidentical family member (a parent, child, or sibling).

Graft-versus-Host Disease and Other Complications

The most prominent complication of allogeneic transplant is graft-versus-host disease, where the donor’s immune cells attack your skin, gut, liver, or other organs. Post-transplant cyclophosphamide has emerged as an effective strategy for preventing severe GVHD. A European study comparing this approach in fully matched and haploidentical transplants for Hodgkin lymphoma found that while haploidentical recipients had a higher rate of moderate-to-severe acute GVHD (about 34% versus 24%), the use of post-transplant cyclophosphamide kept outcomes manageable in both groups.¹¹

Infections are a major concern after any transplant because the immune system takes months to rebuild. After allogeneic transplant, the innate immune system recovers first, while the adaptive arm (the part that remembers and fights specific pathogens) takes much longer, leaving patients vulnerable to different types of infections at different time points.¹² Patients remain on preventive antibiotics, antivirals, and antifungals for months after transplant and need to be vigilant about fever or other signs of infection during recovery.

A less well-known complication is veno-occlusive disease (also called sinusoidal obstruction syndrome), which affects blood flow in the liver and can cause painful liver swelling, fluid retention, and jaundice. It occurs after both autologous and allogeneic transplants, though it is more common with intense conditioning regimens.¹³ In a Spanish study of nearly 800 haploidentical transplants using post-transplant cyclophosphamide, about 6% of patients developed this complication, and among those, roughly 70% had severe or very severe forms.¹⁴ Risk factors include prior liver problems, kidney injury, and certain prior drug exposures, including some newer antibody-drug conjugates used in lymphoma treatment.¹⁵

Secondary Cancers After Transplant

Surviving lymphoma after transplant means living with a moderately elevated risk of developing a second, unrelated cancer later in life. A Danish population-based study found that the risk of a second malignancy at ten years was about 20% in transplant recipients, compared with 14% in matched individuals from the general population. The excess risk was driven overwhelmingly by two categories: non-melanoma skin cancers and blood cancers like myelodysplastic syndrome or acute myeloid leukemia. Solid tumor risk was not significantly different from the general population.¹⁶

A separate analysis found that about 5% of patients developed an invasive second cancer within five years of transplant, rising to 12% at ten years and 21% at twenty years. Risk was higher in older patients and in those with a lymphoma diagnosis specifically (as opposed to myeloma). Encouragingly, nearly half of the solid tumors in that cohort were caught at an early, potentially curable stage.¹⁷ Another study specific to aggressive non-Hodgkin lymphoma found the relative risk of developing acute myeloid leukemia after transplant was about thirteen times the general population rate, and exposure to certain salvage chemotherapy regimens appeared to increase the risk further.¹⁸

The practical takeaway for survivors is that long-term follow-up matters. Regular blood counts can catch early signs of blood-related second cancers, and standard cancer screening (skin checks, age-appropriate solid tumor screening) is especially important for this population.

How CAR-T Cell Therapy Fits In

CAR-T cell therapy, which engineers a patient’s own immune cells to target lymphoma, has become the most prominent alternative to transplant for certain relapsed B-cell lymphomas. The natural question is whether CAR-T replaces transplant. The answer, based on available data, is “not yet for everyone.”

A registry study compared autologous transplant with CAR-T therapy in patients with relapsed DLBCL who were in partial remission after salvage treatment. Transplant patients had a lower rate of disease progression and superior two-year overall survival (about 69% versus 47%), leading the investigators to conclude that transplant remains the standard of care for transplant-eligible patients in partial remission.¹⁹ When the comparison was restricted to patients with two or fewer prior lines of therapy, survival outcomes evened out between the two approaches, though transplant carried slightly higher short-term treatment-related death.²⁰

For patients who relapse after CAR-T therapy, allogeneic transplant can still be an option. A small retrospective study of patients with DLBCL who failed CAR-T and then underwent allogeneic transplant reported a one-year overall survival of 70% and an overall response rate of 60%.²¹ A larger analysis of allogeneic transplant after CAR-T in large B-cell lymphoma found two-year overall survival of 45% and progression-free survival of 31%, modest numbers that nonetheless represent meaningful salvage for patients who have run out of other options.²² Rather than viewing CAR-T and transplant as competitors, many treatment centers now see them as sequential tools in a broader strategy.

What a Pre-Transplant PET Scan Tells You

Before proceeding to autologous transplant, most patients undergo a PET/CT scan to assess how much residual disease remains. This scan is not just a formality: it is one of the strongest predictors of whether transplant will work. In patients with DLBCL, those whose pre-transplant scans showed a near-complete response (scored as Deauville 1 to 3) had a three-year progression-free survival of 64% and overall survival of 84%. Patients with a score of 4, indicating significant residual metabolic activity, had a three-year progression-free survival of 0% and overall survival of just 25%.²³ If your scan shows a poor response to salvage therapy, your doctor may suggest alternative approaches, such as CAR-T or a clinical trial, rather than proceeding directly to transplant.

Fertility and the Importance of Planning Ahead

Transplant conditioning regimens carry an extremely high risk of infertility in both men and women.²⁴ The damage comes primarily from alkylating agents and, when used, total body irradiation. In women, the impact depends heavily on age at the time of treatment, with younger women having somewhat better chances of recovery, though permanent ovarian failure is common after full-intensity conditioning. Every patient should be offered a fertility preservation consultation before starting treatment, ideally before salvage chemotherapy begins, since the earlier steps of treatment also reduce fertility.²⁵ For men, sperm banking is straightforward and widely available. For women, egg or embryo freezing is the standard, though ovarian tissue freezing is an option for those who cannot delay treatment.

Even with reduced-intensity conditioning, where theoretically less gonadal damage occurs, fertility experts still recommend preservation because there is not enough data to predict individual outcomes after these milder regimens. Fertility conversations sometimes get crowded out by the urgency of cancer treatment, so if your team has not raised it, ask.

Financial Strain During and After Transplant

Transplant is expensive, and the costs extend well beyond the hospital bill. A single-center study found that at the time of transplant evaluation, nearly a quarter of patients already reported moderate-to-high financial strain. These patients were cutting spending on food and clothing, drawing down savings, and sometimes skipping prescriptions because of costs. Importantly, financial toxicity also predicted lower quality of life at six months and one year after transplant.²⁶ Higher income was strongly protective, while the financial hit fell hardest on patients with lower earnings.

Families with children undergoing transplant face their own severe pressures. A survey of families of pediatric transplant patients found that 12% of parents had to quit or lost their jobs because of their child’s treatment, and 20% of families lost more than 40% of their annual income. Over a third of families reported food, energy, or housing insecurity during the post-transplant period.²⁷ Many transplant centers have social workers and financial counselors who can help navigate insurance appeals, housing assistance, and charitable funds, but patients often need to ask for these resources proactively.

Life After Transplant and Long-Term Cognitive Health

Survivors often worry about cognitive problems after transplant, sometimes described informally as “chemo brain.” A study of long-term survivors found that, on average, both autologous and allogeneic transplant survivors reported cognitive quality-of-life scores that were right in line with the general population. Factors associated with lower cognitive scores included sleep problems, hearing difficulties, and female sex, but the time since transplant was not, meaning that if cognitive issues exist, they tend to stabilize rather than worsen over the years.²⁸ One unexpected finding was that older survivors actually reported somewhat better cognitive quality of life than younger ones, possibly because older adults have different reference points or expectations.

Maintenance Therapy After Transplant for T-Cell Lymphomas

Most lymphoma transplant research focuses on B-cell subtypes, but T-cell lymphomas are a distinct and more challenging group. Relapse after transplant is a major problem in peripheral T-cell lymphomas, and researchers have been testing whether ongoing drug therapy after transplant can keep the disease at bay. Trials using agents like brentuximab vedotin, romidepsin, and checkpoint inhibitors as post-transplant maintenance have shown early promise in reducing relapse rates.²⁹ This is an active area of clinical trials, and patients with T-cell lymphoma who are heading toward transplant should ask their team about maintenance options.